Tagged with R

Taiwan Dr Hung-Kai Kevin Chen, co-founder and CEO of Elixiron Immunotherapeutics, an innovative rising biotech focused on immunotherapeutic solutions, describes the company’s unique approach to developing new treatment methods for two disease areas with massive unmet medical need: hard-to-treat cancer and chronic hepatitis B. Dr Chen goes on to share his…

Spain Jesús Donado, CEO of B. Braun Spain introduces the company’s strong footprint in Spain, as a manufacturing hub and a global centre of excellence for the company. Donado also discusses the challenge of offering solution and treatment-based services, while having to sell through product and volume-based tenders.   We are…

France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation.   A reform-minded and business-oriented administration under President Emmanuel Macron…

Sweden Sweden’s comprehensive and high-quality system of electronic health records is increasingly in demand from international researchers in the machine learning and AI fields and is also facilitating significant breakthroughs in more traditional medical research.   The Swedish National Patient Register (NPR) contains comprehensive lists of data sorted into four groups:…

Spain Esteve has long been a family-run business, though in early 2018 the Spanish champion decided to make a daring, though calculated, move and positioned the then CCO of Lundbeck, Staffan Schüberg, as their new CEO.   We have world-class experience [in neuroscience and gene therapy] and we see these areas…

France Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for many years, been characterized by its discreet, understated approach and a rugged pragmatism and…

China China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed regions. However, with the rollout of the “4+7” procurement scheme slashing drug prices, industry insiders are predicting a more turbulent…

Switzerland In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants, Roche and Novartis, some of the larger companies in the Swiss pharma sector like Ferring and IBSA are privately held,…

Spain Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant of the limitations and risks of operating within a single market. Therefore, these small to mid-cap local companies are taking the next logical steps in their growth; internationalization.   The financial crisis in 2008 pushed…

France Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million since 2014. It is, however, the company’s unique positioning right at the confluence between the worlds of medicines and cosmetics…

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…

Sweden Gothenburg-headquartered Cellink has gone from a start-up to one of the world’s leading 3D bioprinting firms in just four years; firmly positioning Sweden at the forefront of this potentially revolutionary new technology.   In the coming decade we would like to continue to push the boundaries of 3D bioprinting until…